Pretransplant immunomodulation of highly sensitized small bowel transplant candidates with intravenous immune globulin

Transplantation

Volumn 81, Issue 12, 2006, Pages 1743-1746

  Gondolesi, Gabriel ^a   Blondeau, Benoit ^a   Maurette, Raphael ^a   Hoppenhauer, Laura ^a   Rodriguez Laiz, Gonzalo ^a   Schiano, Thomas ^a   Boros, Peter ^a   Bromberg, Jonathan ^a   Akalin, Enver ^a   Sauter, Bernhard ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Alloimmunization; Immunoglobulins; Intestinal transplantation

Indexed keywords

HUMAN IMMUNOGLOBULIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; ALLOIMMUNIZATION; ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; COST EFFECTIVENESS ANALYSIS; DESENSITIZATION; DISEASE SEVERITY; DRUG COST; FEMALE; GRAFT REJECTION; HEALTH CARE COST; HUMAN; IMMUNOMODULATION; INTESTINE TRANSPLANTATION; MALE; MORTALITY; PLASMAPHERESIS; PREOPERATIVE TREATMENT; PRIORITY JOURNAL;

GRAFT REJECTION; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; INTESTINE, SMALL; MIDDLE AGED; TRANSPLANTATION CONDITIONING;

EID: 33745446460     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000226078.94635.76     Document Type: Article

References (20)

1. Patel R, Terasaki PI. Significance of positive crossmatch test in kidney transplantation. N Engl J Med 1969; 280: 735.
2. Hariharan S, Johnson C, Bresnahan B, et al. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 2000; 342: 605-612.
3. Glotz D, Antoine C, Julia P, et al. Desensitization and subsequent kidney transplantation of patients using intravenous immunoglobulins (IVIg). Am J Transplant 2002; 2: 758.
4. Jordan S. Management of the highly HLA-sensitized patient. A novel role for intravenous gammaglobulin. Am J Transplant 2002; 2: 691.
5. Jordan SC, Vo A, Bunnapradist S, et al. Intravenous immunoglobulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients. Transplantation 2003; 76: 631.
6. Montgomery R, Zachary A, Racusen L, et al. Plasmapheresis and intravenous immunoglobulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match positive recipients. Transplantation 2000; 70: 887.
7. Jordan SC, Tyan D, Stablein D, et al. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial. J Am Soc Nephrol 2004; 15: 3256.
8. Stegall MD, Dean PG, Gloor JM. ABO-incompatible kidney transplantation. Transplantation 2004; 78: 635.
9. Akalin E, Ames S, Sehgal V, et al. Intravenous immunoglobulins and thymoglobulin facilitate kidney transplantation in complement-dependent cytotoxicity B-cell and flow cytometry T- or B-cell cross-match-positive patients. Transplantation 2003; 76: 1444.
10. Akalin E, Bromberg JS. Intravenous immunoglobulin induction treatment in flow cytometry cross-match-positive kidney transplant recipients. Hum Immunol 2005; 66: 359.
11. Fishbein T, Kaufman S, Florman S, et al. Isolated Intestinal Transplantation: proof of efficacy. Transplantation 2003; 76: 636.
12. Fryer J, Pellar S, Ormond D, et al. Mortality in candidates waiting for combined liver-intestine transplants exceeds that for other candidates waiting for liver transplants. Liver Transpl 2003; 9: 748.
13. Bond G, Reyes J, Mazariegos G, et al. The impact of positive T-cell lymphocytotoxic crossmatch on intestinal allograft rejection and survival. Transpl Proceedings 2000; 32: 1197.
14. Wu T, Abu-Elmagd K, Bond J, et al. A clinicopathologic study of isolated intestinal allografts with preformed IgG lymphocytotoxic antibodies. Transplant Proc 2002; 34: 878.
15. Wu T, Abu-Elmagd K, Bond G, Demetris AJ. A clinicopathologic study of isolated intestinal allografts with preformed IgG lymphocytotoxic antibodies. Hum Pathol 2004; 35: 1332.
16. Boros P, Gondolesi G, Bromberg J. High dose intravenous immunoglobulins treatment: mechanism of action. Liver Transpl 2005; 11: 1469.
17. Watanabe J, Scornick J. IVIG and HLA antibodies. Evidence for inhibition of complement activation but not for anti-idiotypic activity. Am J Transpl 2005; 5: 2786.
18. Dwyer JM. Manipulating the immune system with immune globulin. N Engl J Med 1992; 326: 107.
19. Akalin E, Ames S, Sehgal V, et al. Intravenous immunoglobulin and thymoglobulin induction treatment in immunologically high-risk kidney transplant recipients. Transplantation 2005; 27: 79: 742.
20. Casadei DH, del C Rial M, Opelz G, et al. A randomized and prospective study comparing treatment with high-dose intravenous immunoglobulin with monoclonal antibodies for rescue of kidney grafts with steroid-resistant rejection. Transplantation 2001; 71: 53.